N-methylation of anthracyclines modulates their cytotoxicity and pharmacokinetic in wild type and multidrug resistant cells - PubMed (original) (raw)
N-methylation of anthracyclines modulates their cytotoxicity and pharmacokinetic in wild type and multidrug resistant cells
L Gate et al. Biomed Pharmacother. 2003 Sep.
Abstract
Anthracyclines are the most commonly used classes of anticancer agents in chemotherapy. Development of resistance to these molecules is one of the major reasons for treatment failure. The overexpression of the membrane transporter P-glycoprotein (P-gp) is among the principal mechanisms involved in this phenomenon. This pump, which is responsible for the multidrug resistance (MDR) phenotype, decreases the toxicity of a wide range of unrelated anticancer drugs by increasing their cellular efflux. Structure-activity relationship experiments have shown that the positively charged amino group of the anthracyclines could be responsible for their transport by P-gp. Here, we used three new anthracyclines that shared the same chromophore but differed by the degree of N-methylation of their sugar moiety. Oxaunomycin (OXN) possessed a non-methylated amino group, while LB-1 was monomethylated and beta-clamycin T (BCT) was dimethylated. In sensitive cells (FLC), reduced cytotoxicity was related to the level of N-methylation; whereas in resistant cells (DOX-RFLC(1) and DOX-RFLC(2)) overexpressing different levels of P-gp, increased N-methylation enhanced anthracycline cytotoxicity. Decreased resistance in DOX-RFLCs was associated with an increased drug accumulation due to a reduced cellular efflux. As expected, the MDR modulator verapamil decreased resistance to these anthracyclines by increasing the cellular accumulation. These results suggest that N-methylation of anthracyclines circumvents resistance by diminishing drug transport by P-gp in MDR-positive cells. These observations could be the consequence of the steric hindrance created by the methyl group(s) which may impair the interaction between the positively charged amino group and the active site of P-gp.
Similar articles
- Cellular pharmacology of lipophilic anthracyclines in human tumor cells in culture selected for resistance to doxorubicin.
Bennis S, Faure P, Chapey C, Hu YP, Fourche J, El Yamani J, Robert J. Bennis S, et al. Anticancer Drugs. 1997 Jul;8(6):610-7. doi: 10.1097/00001813-199707000-00009. Anticancer Drugs. 1997. PMID: 9300576 - Kinetics of anthracycline efflux from multidrug resistance protein-expressing cancer cells compared with P-glycoprotein-expressing cancer cells.
Marbeuf-Gueye C, Broxterman HJ, Dubru F, Priebe W, Garnier-Suillerot A. Marbeuf-Gueye C, et al. Mol Pharmacol. 1998 Jan;53(1):141-7. doi: 10.1124/mol.53.1.141. Mol Pharmacol. 1998. PMID: 9443942 - Modulation of the spacer in N,N-bis(alkanol)amine aryl ester heterodimers led to the discovery of a series of highly potent P-glycoprotein-based multidrug resistance (MDR) modulators.
Dei S, Braconi L, Trezza A, Menicatti M, Contino M, Coronnello M, Chiaramonte N, Manetti D, Perrone MG, Romanelli MN, Udomtanakunchai C, Colabufo NA, Bartolucci G, Spiga O, Salerno M, Teodori E. Dei S, et al. Eur J Med Chem. 2019 Jun 15;172:71-94. doi: 10.1016/j.ejmech.2019.03.054. Epub 2019 Mar 27. Eur J Med Chem. 2019. PMID: 30947123 - Multidrug resistance-associated protein: a protein distinct from P-glycoprotein involved in cytotoxic drug expulsion.
Barrand MA, Bagrij T, Neo SY. Barrand MA, et al. Gen Pharmacol. 1997 May;28(5):639-45. doi: 10.1016/s0306-3623(96)00284-4. Gen Pharmacol. 1997. PMID: 9184795 Review. - Pharmacological strategies for overcoming multidrug resistance.
Nobili S, Landini I, Giglioni B, Mini E. Nobili S, et al. Curr Drug Targets. 2006 Jul;7(7):861-79. doi: 10.2174/138945006777709593. Curr Drug Targets. 2006. PMID: 16842217 Review.
Cited by
- Novel _N,N_-Dimethyl-idarubicin Analogues Are Effective Cytotoxic Agents for ABCB1-Overexpressing, Doxorubicin-Resistant Cells.
van Gelder MA, Li Y, Wander DPA, Berlin I, Overkleeft HS, van der Zanden SY, Neefjes JJC. van Gelder MA, et al. J Med Chem. 2024 Aug 22;67(16):13802-13812. doi: 10.1021/acs.jmedchem.4c00614. Epub 2024 Aug 1. J Med Chem. 2024. PMID: 39088428 Free PMC article. - Doxorubicin and Aclarubicin: Shuffling Anthracycline Glycans for Improved Anticancer Agents.
Wander DPA, van der Zanden SY, van der Marel GA, Overkleeft HS, Neefjes J, Codée JDC. Wander DPA, et al. J Med Chem. 2020 Nov 12;63(21):12814-12829. doi: 10.1021/acs.jmedchem.0c01191. Epub 2020 Oct 16. J Med Chem. 2020. PMID: 33064004 Free PMC article. - Synthesis and biological activities of a 3'-azido analogue of Doxorubicin against drug-resistant cancer cells.
Yu S, Zhang G, Zhang W, Luo H, Qiu L, Liu Q, Sun D, Wang PG, Wang F. Yu S, et al. Int J Mol Sci. 2012;13(3):3671-3684. doi: 10.3390/ijms13033671. Epub 2012 Mar 19. Int J Mol Sci. 2012. PMID: 22489175 Free PMC article. - Dual targeting of histone deacetylase and topoisomerase II with novel bifunctional inhibitors.
Guerrant W, Patil V, Canzoneri JC, Oyelere AK. Guerrant W, et al. J Med Chem. 2012 Feb 23;55(4):1465-77. doi: 10.1021/jm200799p. Epub 2012 Feb 13. J Med Chem. 2012. PMID: 22260166 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous